Predicting bleeding and clotting risks in acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well a new scoring system predicts bleeding and clotting risks in people newly diagnosed with acute leukemia. By participating, you may help improve how doctors assess and manage these risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute leukemia.
- You must have one of these types: acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), or acute myeloid leukemia (AML).
- You must not have a known history of a family blood clotting disorder (thrombophilia).
- You must not have taken blood thinners or antiplatelet drugs before your leukemia diagnosis.
- You must not have had bleeding problems due to a coagulation disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often hospitalized patients with acute leukemia develop blood clots. By tracking this, doctors hope to learn who might be at higher risk and find better ways to prevent clots in the future.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
This study is beta-testing a new app designed to reduce healthcare disparities among people admitted to the hospital with suspected acute leukemia. Your feedback could help make the app more helpful for future patients.
This study looks at a new way to predict if patients with blood cancers and very low platelets will have bleeding problems. By doing extra blood tests, researchers hope to create a score that helps doctors prevent bleeds.
This study looks at how blood and clotting are affected in people newly diagnosed with acute myeloid leukemia (AML) who receive a common intensive chemotherapy combination (idarubicin and cytarabine). The goal is to better understand blood-related side effects and improve care.
This study looks at whether a simple blood test can help predict outcomes in patients with newly diagnosed acute leukemia. The test measures the ratio of two proteins in your blood, which might give doctors clues about how the disease will progress.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.